Genentech Offers Secret Rebates to Promote Lucentis. TweetPharm Pharma Social Media Infographic. Top Pharma Tweeters: Tracking Pharma’s Use of Twitter in Real-Time. About a year ago, I published a chart that looked like the one to the right in a post titled "Pharma Finds its Voice on Twitter.
" This functional but not-so-pretty graphic featured known pharma companies actively tweeting, their Twitter handle, the date they joined, and the number of following, followers, and updates. The pharma community response was positive, and everyone seemed to appreciate having a central resource for this type of info. Photo : yfrog.com/0quh4dj - Shared by ulfw. An Overview of Molecular Markers in Lung Cancer. Introduction to Molecular Markers A molecular marker is an identifiable molecular characteristic (usually DNA, RNA, or protein) in a patient or a tumor that can be used to provide prognostic or predictive information about the cancer or about a particular treatment.
Metastatic melanoma – what’s new on the horizon? Metastatic melanoma is quite a hot topic right now with a rich pipeline of products in development after a decade of little or no progress.
Of course, it is a bit like three London buses coming along at once after an hour long wait in the winter weather, but better late than never. Many of you will remember the recent data from ipilimumab (BMS), an immunotherapy that showed increased survival, albeit with some severe adverse events, from the phase III trial in newly diagnosed metastatic melanoma presented at ASCO in the plenary session earlier this year, followed by a publication in the NEJM. The FDA filing was subsequently submitted on the basis of the positive data. Yesterday, BMS announced that the FDA have moved the PDUFA date back 3 months from Dec 25th to March 26th, 2011. Pastis. Leshalles.net. MARCONY RISTORANTE. Balthazar Restaurant. Interesting infographic looking at the change in job creation over the last 18 months Red is job losses Blue is gains. The Fed's $600 Billion Statement, Translated Into Plain English : Planet Money. Jose Luis Magana/AP Note: This post was originally published on Weds., Nov. 3.
The Federal Reserve is about to create $600 billion out of thin air. It's a huge, experimental stimulus program that will affect stock markets and government policies around the world. But the Fed announced its plan in a statement written largely in jargon and code. Washingtonpost.com. Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium. Published on November 1, 2010 at 8:23 AM Oncolytics Biotech Inc. Home. @jaysbryant hmm good point, much better than mine: Orbiting Outpost: ISS. Chinese Mustard Greens at Stokes Farm. Metastatic melanoma – what’s new on the horizon? Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology. Dendreon’s Provenge Launch Story Enters Second Chapter, With Today’s Earnings Call. Luke Timmerman11/3/10 Dendreon, the Seattle-based cancer drug developer that people either love or love to hate, is going to provide a lot more grist for debate later today.
The company is preparing to release its third quarter financial report today at the close of markets, and will host a webcast conference call at 4:30 pm Eastern/1:30 pm Pacific to discuss the performance with investors. Altimeter Report: Social Commerce, How Brands Are Generating Revenue by @lcecere. I’m frequently asked “What’s the top challenge the corporate social strategist is struggling” and over and over, ROI comes up very high.
To tackle this challenge head on, Altimeter has conducted a research project to find out how companies are connecting social technologies to the overall buying process as well as analyzing how they increase revenues for brands. Improved survival with ipilimumab in metastatic melanoma. The latest New England Journal of Medicine dropped in the mail yesterday afternoon, it has some interesting articles on how palliation plus chemotherapy offers improved survival over chemo alone and a small study on the positive impact of T'ai Chi on fibromyalgia.
My attention, however, was drawn to the ipilimumab data in advanced metastatic melanoma. We saw the first major presentation of this phase III trial recently at ASCO, and my pre-ASCO notes can be found here. At the BMS investor meeting held during the conference, the executives were clearly very excited about the prospects for the agent. It would seem that the FDA agrees with them, as it was announced yesterday that Priority review status has been granted in previously treated people with melanoma. The PDUFA action date is estimated as December 25th, 2010, so I think we can safely assume that it will likely happen a bit before that.
US election results 2010: live updates. Good evening and welcome to the Guardian's live coverage of the 2010 election results for the US midterm battlefield.
Phone Disk - iPad, iTouch, iPhone Disk Mode for Mac and PC. 10 Web 2.0 Resources You Can Use to Find Digital Inspirations. Digital case study: Swedish Medical Center. When you work in the health care industry in the digital realm, there really is only one case study that matters: Mayo Clinic.
Over the last few years, Lee Aase has set the bar remarkably high when it comes to digital PR and social media marketing in the health care world. But, a few other hospitals and health systems are starting to emerge. Namely, Swedish Medical Center in the Seattle area. Great message! Links to chemical compounds now enabled. The molecular pathology of cancer: a glimpse into the future. Here’s a nice paper that I’ve been reading, written by Tim Harris and Frank McCormick on cancer biology.
Lately, we’ve all seen how advances in DNA sequencing and genome-wide association studies (GWAS) are driving the discovery of the germline and somatic mutations that are present in different cancers. This article sets out to review: “The most important molecular changes in different cancers from the perspective of what should be analyzed on a routine basis in the clinic.” Essentially, this is an overview of where we are in both hematologic and solid tumours and looks at the molecular subsets that are emerging, hopefully as targets for therapeutic intervention. I’m not going to repeat their excellent article, but if you are really interested in this field, I highly recommend reading it. What struck me most though, was not the nice summary of what we know about the biology of cancer, but their vision of the future in cancer medicine:
The Evolving Role of Molecular Markers in the Management of Non-Small Cell Lung Cancer. The Importance of Identifying Molecular Markers in Non-Small Cell Lung Cancer To understand the importance of molecular markers in the current and future treatment of lung cancer, one should first understand how lung cancer was classified up until the beginning of this decade. Pathologists would look at a sample of a patient’s lung tumor under a microscope, and then make a judgment of whether the cells represented small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC).
"Yfrog" Photo : yfrog.com/3d7wxhj - "Shared" by realpatriots. Bogus Grass-Roots Politics on Twitter. Researchers have found evidence that political campaigns and special-interest groups are using scores of fake Twitter accounts to create the impression of broad grass-roots political expression. A team at Indiana University used data-mining and network-analysis techniques to detect the activity.
Women Helping Women: Breast Health Collaborative of Texas. Mobile-apps-for-life-sciences-researchers from biojobblog.com. There is no question that mobile apps are de rigueur and like other mobile devices users, life science researchers are beginning to regularly use them! The molecular pathology of cancer: a glimpse into the future. The Ultimate Dropbox Toolkit & Guide. Pharma Strategy Blog conference newsletter. Pharma Strategy Blog conference newsletter. Hemberger and Pedersen 330 (6004): 598. Crizotinib in ALK-rearranged cancer mutations. While reading the latest New England Journal of Medicine, it was hard not to notice the focus on ALK mutations and crizotinib (Pfizer), with four articles in all on the topic, including a full original article, two brief reports and an editorial to boot.
Historical background Gradually, we are gradually seeing more specific molecular markers and targets evolve in non-small cell lung cancer (NSCLC), which is a particularly difficult cancer to treat. This is good news because if we have a relevant target, we can treat subsets of patients with specific drugs and increase their chances of better outcomes while sparing those who are unlikely to respond from the systemic effects of a potent drug. Many call this ‘personalised medicine’ but I prefer to think of it as targeted therapy, because we are essentially matching the drug to the patient’s needs using biomarkers.
Crizotinib in ALK-rearranged cancer mutations. IPad a Therapeutic Marvel for Disabled People. Who “Owns” Social Media? Answered! October 29, 2010 by Steve Woodruff.